Key result
Targeted gene therapies emerge as promising preclinical strategies for atrial fibrillation.
Why the study?
Current treatments for atrial fibrillation are suboptimal due to limited understanding of the molecular mechanisms underlying AF.
Recent advances in understanding the molecular mechanisms of atrial fibrillation have led to the preclinical development of targeted gene therapies.
Gene-based AF therapies remain preclinical; leaves open clinical translation and efficacy.
Atrial fibrillation (AF) is the most common arrhythmia and a major cause of morbidity and mortality in an aging population. Unfortunately, current treatments for AF are suboptimal, in large part because the molecular mechanisms underlying AF are not well understood. Recent advances in our understanding of the AF disease state have led to the preclinical development of gene-based therapies that are targeted to key molecular mechanisms involved in the genesis and maintenance of AF.
No takes yet. Share an insight, caveat, or question.
Rishi Arora (2017) conducted a review in Atrial fibrillation in heart failure. Gene-based therapies was evaluated. Recent advances in understanding the molecular mechanisms of atrial fibrillation have led to the preclinical development of targeted gene-based therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: